Cargando…

Renal Injury during Long-Term Crizotinib Therapy

Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuma, Taro, Kobayashi, Tetsu, D’Alessandro-Gabazza, Corina N., Fujimoto, Hajime, Ito, Kentaro, Nishii, Yoichi, Nishihama, Kota, Baffour Tonto, Prince, Takeshita, Atsuro, Toda, Masaaki, Gabazza, Esteban C., Taguchi, Osamu, Yonemura, Shigenori, Hataji, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213486/
https://www.ncbi.nlm.nih.gov/pubmed/30257437
http://dx.doi.org/10.3390/ijms19102902
Descripción
Sumario:Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy.